TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Launched by TIZONA THERAPEUTICS, INC · Jul 21, 2020

Keywords

ClinConnect Summary

This clinical trial, called TTX-080-001, is looking at a new treatment for patients with advanced cancers that have not responded well to other therapies. The main goal is to test the safety and effectiveness of a drug called TTX-080, which works by blocking a protein called HLA-G that may help cancer cells survive. Participants in the trial may receive TTX-080 alone or in combination with other cancer treatments, like pembrolizumab or cetuximab. The study is currently recruiting patients who are 18 years or older and have a confirmed diagnosis of advanced or metastatic cancer, meaning the cancer has spread beyond its original location.

To join the trial, patients should have measurable disease and a good overall health status, indicated by a specific performance score. However, certain individuals may be excluded, such as those with severe allergies to similar medications or those currently using other investigational drugs. Participants can expect to have regular check-ups and monitoring throughout the study to assess how well they are responding to the treatment and to ensure their safety. This trial could be an important step in finding new options for people battling difficult cancers.

Gender

ALL

Eligibility criteria

• Abbreviated Inclusion Criteria:
• • 1. Subject with histological diagnosis of advanced/metastatic cancer
• • 2. Age 18 years or older, is willing and able to provide informed consent
• • 3. Evidence of measurable disease
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks
• Abbreviated Exclusion Criteria:
• • 1. History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody
• • 2. Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study
• • 3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
• • 4. History of severe autoimmune disease
• • 5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment